Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selection of therapy: rational decisions based on molecular events.

Hematology/oncology clinics of North America - 1 Oct 2011

Khorashad Jamshid S, Deininger Michael W N

Abstract excerpt

This article reviews to what extent molecular data can be used to rationalize therapeutic choices in the treatment of chronic myeloid leukemia. Two categories of data are discussed: markers that globally measure risk but do not provide a molecular rationale for therapy selection; and biomarkers with a causal link to a clinical phenotype, such as certain mutations of the BCR-ABL kinase domain. As therapy selection...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to BCR gene
Share to Genes, abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Mutation

Share to Prognosis

Share to Protein Structure, Tertiary

Source

Open in PubMed Open full text

Identifiers

PMID: 22054732
DOI: 10.1016/j.hoc.2011.09.006
PMCID: PMC3251311

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selection of therapy: rational decisions based on molecular events.PMID 22054732Read ↗

Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?Semantic proximity Read ↗

[Recommendations from the GBMHM and the Fi-LMC for the diagnosis and management of chronic myeloid leukemia].Semantic proximity Read ↗

Best Practices in Chronic Myeloid Leukemia Monitoring and Management.Semantic proximity Read ↗

Prognostic factors in chronic myeloid leukaemia therapySemantic proximity Read ↗

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemiaSemantic proximity Read ↗

Treatment and molecular monitoring update in chronic myeloid leukemia management.Semantic proximity Read ↗

Biomarkers in chronic lymphocytic leukemia: Clinical applications and prognostic markersSemantic proximity Read ↗

Evaluating treatment response of chronic myeloid leukemia: emerging science and technology.Semantic proximity Read ↗

Acute myeloid leukemia: 2014 update on risk-stratification and management.Semantic proximity Read ↗

Prognostic factors in acute myeloid leukemia.Semantic proximity Read ↗

Beyond BCR::ABL1—The Role of Genomic Analyses in the Management of CMLSemantic proximity Read ↗

Therapeutic Targeting of BCR-ABL: Prognostic Markers of Response and Resistance Mechanism in Chronic Myeloid LeukaemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.